+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
ID06009874

Early Use of Sodium-Glucose Cotransporter-2 Inhibitors to Protect the Heart in Acute Myocardial Infarction Patients

Led by Mohammad Hussien Tantawy Soliman · Updated on 2026-10-14

80

Participants Needed

1

Research Sites

43 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the cardioprotective effects of early administration of dapagliflozin DAPA, a sodium-glucose cotransporter-2 inhibitor, in patients who experience acute myocardial infarction AMI. The study focuses on whether giving DAPA during ischemia and before primary percutaneous coronary intervention pPCI can reduce infarct size, myocardial damage from reperfusion injury, and protect against heart failure HF and acute kidney injury AKI. This area lacks sufficient data, especially regarding the protective effects of DAPA when started early in AMI patients. Participants are randomly assigned to receive either dapagliflozin 10 mg once daily or a matching placebo for three months, starting as early as possible before pPCI. The study compares these two groups to evaluate the effects of the drug on heart and kidney function. The treatment period lasts three months, during which participants continue the assigned medication daily. Throughout the study, participants undergo follow-up assessments to measure infarct size and cardiac biomarkers, including NT-proBNP levels and estimated glomerular filtration rate eGFR, at three months. These measurements help assess heart damage, heart failure risk, and kidney function. The study monitors participants regularly during the treatment period to evaluate the drugs impact and safety over the three months of therapy.

CONDITIONS

Brief Title

Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI

Research Team

M

Mohammad Soliman

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here